Cell Surface Marker Expression in Autoimmune Diseases

This study is designed to explore the expression of cell-surface markers in the following seven disease areas: (a) systemic lupus erythematosus, (b) Sjogren's syndrome, (c) multiple sclerosis, (d) systemic sclerosis, (e) Crohn's disease, (f) ulcerative colitis and (g) inflammatory myositis.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Systemic Lupus Erythematosus Arthritis Arthritis, Rheumatoid Autoimmune Diseases Autoimmune Diseases of the Nervous System Colitis Colitis, Ulcerative Colonic Diseases Connective Tissue Diseases Crohn Disease Crohn's Disease Demyelinating Autoimmune Diseases, CNS Demyelinating Diseases Digestive System Diseases Dry Eye Syndromes Eye Diseases Gastroenteritis Gastrointestinal Diseases Immune System Diseases Inflammatory Bowel Diseases Inflammatory Myositis Intestinal Diseases Joint Diseases Lacrimal Apparatus Diseases Lupus Erythematosus, Systemic Mouth Diseases Multiple Sclerosis Musculoskeletal Diseases Nervous System Diseases Rheumatic Diseases Salivary Gland Diseases Scleroderma, Systemic Sjogren's Syndrome Skin Diseases Skin and Connective Tissue Diseases Stomatognathic Diseases Systemic Sclerosis Ulcerative Colitis Xerostomia

Age range

19 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

GI Research Institute, Vancouver, British Columbia, Canada

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Male or female participants 19 years of age or older.
Participant or legal surrogate able and willing to provide written, informed consent.
Participant is, or has been undergoing care for one of the specified diseases in a participating centre with a confirmed clinical diagnosis of the specified disease.
Participant has or will provide the relevant peripheral blood (required) and normal practice tissue specimens (if available).
Participant has one of the following target auto-immune or inflammatory diseases diagnosed according to local clinical practice guidelines:

Crohn's Disease
Inflammatory myositis
Multiple sclerosis
Sjogren's syndrome
Systemic lupus erythematosus
Systemic sclerosis
Ulcerative colitis

Exclusion criteria

Participants receiving investigational therapy within 30 days or 5 half-lives, whichever is longer, prior to enrolment.
Participants suffering from any additional disease that may interfere with the biomarker signals as per the investigator's discretion.

Treatment and study plan

Primary outcomes

CD28 Expression

Time frame: At enrollment

Percentage of CD28+ T cells in peripheral blood
ICOS Expression

Time frame: At enrollment

Percentage of ICOS+ T cells in peripheral blood

Sponsors and collaborators

Lead sponsor

Alpine Immune Sciences, Inc.

Industry

Registry information

Official study title

A Cross-Sectional Study of Cell Surface Marker Expression in Participants With Autoimmune or Inflammatory Diseases

Acronym: CASCADE

Important dates

Study start: 2019
Primary completion: 2019
Study completion: 2019
First posted: Nov 28, 2018
Registry last updated: Aug 27, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed